Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.050 | GeneticVariation | BEFREE | Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. | 31184237 | 2019 |
||||
|
0.050 | GeneticVariation | BEFREE | In a cohort of 23 PCNSL patients, L265P MYD88 mutations were examined in tumor-free BM mononuclear cells (MNC) in which the PCNSL tumors had L265P MYD88 mutations. | 30353605 | 2019 |
||||
|
0.050 | GeneticVariation | BEFREE | The MyD88 L265P mutation predicted a poor prognosis in elderly PCNSL patients. | 29258950 | 2018 |
||||
|
0.050 | GeneticVariation | BEFREE | To investigate how sensitively the MYD88 L265P mutation can be identified in cell-free DNA from PCNSL patients, we carried out droplet digital PCR (ddPCR) and targeted deep sequencing (TDS) in 14 consecutive PCNSL patients from whom paired tumor-derived DNA and cell-free DNA was available at diagnosis. | 29151258 | 2018 |
||||
|
0.050 | GeneticVariation | BEFREE | Nine of these samples tested positive for MYD88 p.(L265P) (8 LPL and 1 PCNSL). | 29210102 | 2018 |
||||
|
0.010 | GeneticVariation | BEFREE | Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate. | 27781293 | 2017 |
||||
|
0.010 | GeneticVariation | BEFREE | Furthermore, for the methylenetetrahydrofolate reductase (MTHFR) c.1298A > C (E429A) polymorphism the mutated C-allele was found more frequently among PCNSL patients than among population controls (P = 0.026; OR = 1.57; 1.05-2.34). | 20237949 | 2010 |
||||
|
0.010 | GeneticVariation | BEFREE | The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. | 15138479 | 2004 |